Publications
Found 6 results
Filters: Author is M.R. Melo [Clear All Filters]
, “Increased androgen receptor messenger RNA in frontal-parietal hair follicles of women with androgenetic alopecia”, vol. 12, pp. 1834-1840, 2013.
, “Persistent glucocorticoid resistance in systemic lupus erythematosus patients during clinical remission”, vol. 12, pp. 2010-2019, 2013.
, “Tissue-specific adaptive levels of glucocorticoid receptor alpha mRNA and their relationship with insulin resistance”, vol. 11, pp. 3975-3987, 2012.
Anagnostis P, Athyros VG, Tziomalos K, Karagiannis A, et al. (2009). Clinical review: the pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. J. Clin. Endocrinol. Metab. 94: 2692-2701.
http://dx.doi.org/10.1210/jc.2009-0370
PMid:19470627
Balachandran A, Guan H, Sellan M, van US, et al. (2008). Insulin and dexamethasone dynamically regulate adipocyte 11beta-hydroxysteroid dehydrogenase type 1. Endocrinology 149: 4069-4079.
http://dx.doi.org/10.1210/en.2008-0088
PMid:18467433 PMCid:2488250
Bansilal S, Farkouh ME and Fuster V (2007). Role of insulin resistance and hyperglycemia in the development of atherosclerosis. Am. J. Cardiol. 99: 6B-14B.
http://dx.doi.org/10.1016/j.amjcard.2006.11.002
PMid:17307054
Benetos A, Thomas F, Pannier B, Bean K, et al. (2008). All-cause and cardiovascular mortality using the different definitions of metabolic syndrome. Am. J. Cardiol. 102: 188-191.
http://dx.doi.org/10.1016/j.amjcard.2008.03.037
PMid:18602519
Deveci E, Yesil M, Akinci B, Yesil S, et al. (2009). Evaluation of insulin resistance in normoglycemic patients with coronary artery disease. Clin. Cardiol. 32: 32-36.
http://dx.doi.org/10.1002/clc.20379
PMid:19143010
Di Blasio AM, van Rossum EF, Maestrini S, Berselli ME, et al. (2003). The relation between two polymorphisms in the glucocorticoid receptor gene and body mass index, blood pressure and cholesterol in obese patients. Clin. Endocrinol. 59: 68-74.
http://dx.doi.org/10.1046/j.1365-2265.2003.01798.x
Duma D, Jewell CM and Cidlowski JA (2006). Multiple glucocorticoid receptor isoforms and mechanisms of post-translational modification. J. Steroid Biochem. Mol. Biol. 102: 11-21.
http://dx.doi.org/10.1016/j.jsbmb.2006.09.009
PMid:17070034
Escher G, Galli I, Vishwanath BS, Frey BM, et al. (1997). Tumor necrosis factor alpha and interleukin 1beta enhance the cortisone/cortisol shuttle. J. Exp. Med. 186: 189-198.
http://dx.doi.org/10.1084/jem.186.2.189
PMid:9221748 PMCid:2198986
Faria CD, Castro RB, Longui CA, Kochi C, et al. (2010). Impact of prolonged low-grade physical training on the in vivo glucocorticoid sensitivity and on glucocorticoid receptor-alpha mRNA levels of obese adolescents. Horm. Res. Paediatr. 73: 458-464.
http://dx.doi.org/10.1159/000313591
PMid:20407233
Fernandes-Rosa FL, Bueno AC, de Souza RM, de CM, et al. (2010). Mineralocorticoid receptor p.I180V polymorphism: association with body mass index and LDL-cholesterol levels. J. Endocrinol. Invest. 33: 472-477.
PMid:19955850
Gathercole LL, Bujalska IJ, Stewart PM and Tomlinson JW (2007). Glucocorticoid modulation of insulin signaling in human subcutaneous adipose tissue. J. Clin. Endocrinol. Metab. 92: 4332-4339.
http://dx.doi.org/10.1210/jc.2007-1399
PMid:17711920
Geloneze B, Repetto EM, Geloneze SR, Tambascia MA, et al. (2006). The threshold value for insulin resistance (HOMA-IR) in an admixtured population IR in the Brazilian Metabolic Syndrome Study. Diabetes Res. Clin. Pract. 72: 219-220.
http://dx.doi.org/10.1016/j.diabres.2005.10.017
PMid:16310881
Georgakopoulos A and Tsawdaroglou N (1996). Insulin potentiates the transactivation potency of the glucocorticoid receptor. FEBS Lett. 381: 177-182.
http://dx.doi.org/10.1016/0014-5793(96)00115-9
Gesina E, Blondeau B, Milet A, Le N, I, et al. (2006). Glucocorticoid signalling affects pancreatic development through both direct and indirect effects. Diabetologia 49: 2939-2947.
http://dx.doi.org/10.1007/s00125-006-0449-3
PMid:17001468 PMCid:1885455
Goedecke JH, Wake DJ, Levitt NS, Lambert EV, et al. (2006). Glucocorticoid metabolism within superficial subcutaneous rather than visceral adipose tissue is associated with features of the metabolic syndrome in South African women. Clin. Endocrinol. 65: 81-87.
http://dx.doi.org/10.1111/j.1365-2265.2006.02552.x
PMid:16817824
Gross KL, Lu NZ and Cidlowski JA (2009). Molecular mechanisms regulating glucocorticoid sensitivity and resistance. Mol. Cell Endocrinol. 300: 7-16.
http://dx.doi.org/10.1016/j.mce.2008.10.001
PMid:19000736 PMCid:2674248
Hoppmann J, Perwitz N, Meier B, Fasshauer M, et al. (2010). The balance between gluco- and mineralo-corticoid action critically determines inflammatory adipocyte responses. J. Endocrinol. 204: 153-164.
http://dx.doi.org/10.1677/JOE-09-0292
PMid:19939912
Longui CA and Faria CD (2009). Evaluation of glucocorticoid sensitivity and its potential clinical applicability. Horm. Res. 71: 305-309.
http://dx.doi.org/10.1159/000223413
PMid:19506386
Löwenberg M, Tuynman J, Scheffer M, Verhaar A, et al. (2006). Kinome analysis reveals nongenomic glucocorticoid receptor-dependent inhibition of insulin signaling. Endocrinology 147: 3555-3562.
http://dx.doi.org/10.1210/en.2005-1602
PMid:16574792
Lu NZ and Cidlowski JA (2005). Translational regulatory mechanisms generate N-terminal glucocorticoid receptor isoforms with unique transcriptional target genes. Mol. Cell 18: 331-342.
http://dx.doi.org/10.1016/j.molcel.2005.03.025
PMid:15866175
Lundgren M, Buren J, Ruge T, Myrnas T, et al. (2004). Glucocorticoids down-regulate glucose uptake capacity and insulin-signaling proteins in omental but not subcutaneous human adipocytes. J. Clin. Endocrinol. Metab. 89: 2989-2997.
http://dx.doi.org/10.1210/jc.2003-031157
PMid:15181089
Masuzaki H, Paterson J, Shinyama H, Morton NM, et al. (2001). A transgenic model of visceral obesity and the metabolic syndrome. Science 294: 2166-2170.
http://dx.doi.org/10.1126/science.1066285
PMid:11739957
Melo MR, Faria CD, Melo KC, Reboucas NA, et al. (2004). Real-time PCR quantitation of glucocorticoid receptor alpha isoform. BMC Mol. Biol. 5: 19.
http://dx.doi.org/10.1186/1471-2199-5-19
PMid:15507144 PMCid:529441
Mericq V, Medina P, Bouwman C, Johnson MC, et al. (2009). Expression and activity of 11beta-hydroxysteroid dehydrogenase type 1 enzyme in subcutaneous and visceral adipose tissue of prepubertal children. Horm. Res. 71: 89-93.
http://dx.doi.org/10.1159/000183897
PMid:19129713
Reaven GM (2008). Insulin resistance: the link between obesity and cardiovascular disease. Endocrinol. Metab. Clin. North Am. 37: 581-viii.
http://dx.doi.org/10.1016/j.ecl.2008.06.005
PMid:18775353
Rebuffé-Scrive M, Bronnegard M, Nilsson A, Eldh J, et al. (1990). Steroid hormone receptors in human adipose tissues. J. Clin. Endocrinol. Metab. 71: 1215-1219.
http://dx.doi.org/10.1210/jcem-71-5-1215
PMid:2229280
Reynolds RM, Chapman KE, Seckl JR, Walker BR, et al. (2002). Skeletal muscle glucocorticoid receptor density and insulin resistance. JAMA 287: 2505-2506.
http://dx.doi.org/10.1001/jama.287.19.2505
PMid:12020330
Rosenbaum P and Ferreira SRG (2003). An update on cardiovascular risk of metabolic syndrome. Arq. Bras. Endocrinol. Metab. 47: 220-227.
http://dx.doi.org/10.1590/S0004-27302003000300004
Sousa Silva T, Longui CA, Rocha MN, Faria CD, et al. (2010). Prolonged physical training decreases mRNA levels of glucocorticoid receptor and inflammatory genes. Horm. Res. Paediatr. 74: 6-14.
http://dx.doi.org/10.1159/000313586
PMid:20407229
Stewart PM (2005). Tissue-specific Cushing's syndrome uncovers a new target in treating the metabolic syndrome - 11beta-hydroxysteroid dehydrogenase type 1. Clin. Med. 5: 142-146.
PMid:15847006
Vegiopoulos A and Herzig S (2007). Glucocorticoids, metabolism and metabolic diseases. Mol. Cell Endocrinol. 275: 43-61.
http://dx.doi.org/10.1016/j.mce.2007.05.015
PMid:17624658
Wake DJ, Rask E, Livingstone DE, Soderberg S, et al. (2003). Local and systemic impact of transcriptional up-regulation of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue in human obesity. J. Clin. Endocrinol. Metab. 88: 3983-3988.
http://dx.doi.org/10.1210/jc.2003-030286
PMid:12915696
Wallace AD and Cidlowski JA (2001). Proteasome-mediated glucocorticoid receptor degradation restricts transcriptional signaling by glucocorticoids. J. Biol. Chem. 276: 42714-42721.
http://dx.doi.org/10.1074/jbc.M106033200
PMid:11555652
Wallace TM, Levy JC and Matthews DR (2004). Use and abuse of HOMA modeling. Diabetes Care 27: 1487-1495.
http://dx.doi.org/10.2337/diacare.27.6.1487
PMid:15161807
Wang M (2005). The role of glucocorticoid action in the pathophysiology of the Metabolic Syndrome. Nutr. Metab. 2: 3.
http://dx.doi.org/10.1186/1743-7075-2-3
PMid:15689240 PMCid:548667
Wassink AM, Van Der Graaf Y, Olijhoek JK and Visseren FL (2008). Metabolic syndrome and the risk of new vascular events and all-cause mortality in patients with coronary artery disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm. Eur. Heart J. 29: 213-223.
http://dx.doi.org/10.1093/eurheartj/ehm582
PMid:18199567
Webster JC, Jewell CM, Bodwell JE, Munck A, et al. (1997). Mouse glucocorticoid receptor phosphorylation status influences multiple functions of the receptor protein. J. Biol. Chem. 272: 9287-9293.
http://dx.doi.org/10.1074/jbc.272.14.9287
PMid:9083064
Whorwood CB, Donovan SJ, Wood PJ and Phillips DI (2001). Regulation of glucocorticoid receptor alpha and beta isoforms and type I 11beta-hydroxysteroid dehydrogenase expression in human skeletal muscle cells: a key role in the pathogenesis of insulin resistance? J. Clin. Endocrinol. Metab. 86: 2296-2308.
http://dx.doi.org/10.1210/jc.86.5.2296
PMid:11344242
Whorwood CB, Donovan SJ, Flanagan D, Phillips DI, et al. (2002). Increased glucocorticoid receptor expression in human skeletal muscle cells may contribute to the pathogenesis of the metabolic syndrome. Diabetes 51: 1066-1075.
http://dx.doi.org/10.2337/diabetes.51.4.1066
PMid:11916927
Zennaro MC, Caprio M and Feve B (2009). Mineralocorticoid receptors in the metabolic syndrome. Trends Endocrinol. Metab. 20: 444-451.
http://dx.doi.org/10.1016/j.tem.2009.05.006
PMid:19800255
, “Quantitation of glucocorticoid receptor alpha and NF-κB pathway mRNA and its correlation with disease activity in rheumatoid arthritis patients”, vol. 9, pp. 2300-2310, 2010.
American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines (2002). Guidelines for the management of rheumatoid arthritis. Arthitis Rheum. 46: 328-346.
http://dx.doi.org/10.1002/art.10148
PMid:11840435
Asahara H, Fujisawa K, Kobata T, Hasunuma T, et al. (1997). Direct evidence of high DNA binding activity of transcription factor AP-1 in rheumatoid arthritis synovium. Arthritis Rheum. 40: 912-918.
http://dx.doi.org/10.1002/art.1780400520
PMid:9153554
Baeuerle PA and Baltimore D (1996). NF-kappa B: ten years after. Cell 87: 13-20.
http://dx.doi.org/10.1016/S0092-8674(00)81318-5
Baldwin AS Jr (1996). The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu. Rev. Immunol. 14: 649-683.
http://dx.doi.org/10.1146/annurev.immunol.14.1.649
PMid:8717528
Bértolo MB, Brenol CV, Schainberg CG, Neubarth F, et al. (2007). Atualização do consenso brasileiro no diagnóstico e tratamento da artrite reumatóide. Rev. Bras. Reumatol. 47: 151-159.
Boss B and Neeck G (2000). Correlation of IL-6 with the classical humoral disease activity parameters ESR and CRP and with serum cortisol, reflecting the activity of the HPA axis in active rheumatoid arthritis. Z. Rheumatol. (Suppl 2) 59: II-62-II-64.
http://dx.doi.org/10.1007/s003930070020
Brenol CV, Monticielo OA, Xavier RM and Brenol JCT (2007). Artrite reumatóide e aterosclerose. Rev. Assoc. Med. Bras. 53: 465-470.
http://dx.doi.org/10.1590/S0104-42302007000500026
PMid:17952359
Callahan LF, Pincus T, Huston JW III, Brooks RH, et al. (1997). Measures of activity and damage in rheumatoid arthritis: depiction of changes and prediction of mortality over five years. Arthritis Care Res. 10: 381-394.
http://dx.doi.org/10.1002/art.1790100606
PMid:9481230
Carlsson AM (1983). Assessment of chronic pain. I. Aspects of the reliability and validity of the visual analogue scale. Pain 16: 87-101.
http://dx.doi.org/10.1016/0304-3959(83)90088-X
Cobra JF, Melo MR, Faria CD, Longui CA, et al. (2009). Simultaneous evaluation of in vivo glucocorticoid sensitivity and expression of glucocorticoid receptor alpha-isoform in rheumatoid arthritis patients. Arq. Bras. Endocrinol. Metabol. 53: 24-30.
http://dx.doi.org/10.1590/S0004-27302009000100005
PMid:19347182
Crofford LJ, Kalogeras KT, Mastorakos G, Magiakou MA, et al. (1997). Circadian relationships between interleukin (IL)- 6 and hypothalamic-pituitary-adrenal axis hormones: failure of IL-6 to cause sustained hypercortisolism in patients with early untreated rheumatoid arthritis. J. Clin. Endocrinol. Metab. 82: 1279-1283.
http://dx.doi.org/10.1210/jc.82.4.1279
PMid:9100607
De Bosscher K, Vanden Berghe W and Haegeman G (2001). Glucocorticoid repression of AP-1 is not mediated by competition for nuclear coactivators. Mol. Endocrinol. 15: 219-227.
http://dx.doi.org/10.1210/me.15.2.219
PMid:11158329
Eggert M, Schulz M and Neeck G (2001). Molecular mechanisms of glucocorticoid action in rheumatic autoimmune diseases. J. Steroid Biochem. Mol. Biol. 77: 185-191.
http://dx.doi.org/10.1016/S0960-0760(01)00058-9
Eggert M, Kluter A, Rusch D, Schmidt KL, et al. (2002). Expression analysis of the glucocorticoid receptor and the nuclear factor-kB subunit p50 in lymphocytes from patients with rheumatoid arthritis. J. Rheumatol. 29: 2500-2506.
PMid:12465142
Faria CD, Cobra JF, Sousa E Silva, Melo MR, et al. (2008). A very low dose intravenous dexamethasone suppression test as an index of glucocorticoid sensitivity. Horm. Res. 69: 357-362.
http://dx.doi.org/10.1159/000117392
PMid:18504395
Faria CDC, Castro RB, Longui CA, Kochi C, et al. (2010). Impact of prolonged low-grade physical training on the in vivo glucocorticoid sensitivity and on glucocorticoid receptor mRNA levels of obese adolescents. Horm. Res. Paediatr. 73: 458-464.
http://dx.doi.org/10.1159/000313591
PMid:20407233
Firestein GS (2004). NF-kappaB: Holy Grail for rheumatoid arthritis? Arthritis Rheum. 50: 2381-2386.
http://dx.doi.org/10.1002/art.20468
PMid:15334448
Fries JF, Spitz PW and Young DY (1982). The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J. Rheumatol. 9: 789-793.
PMid:7175852
Fujisawa K, Aono H, Hasunuma T, Yamamoto K, et al. (1996). Activation of transcription factor NF-kappa B in human synovial cells in response to tumor necrosis factor alpha. Arthritis Rheum. 39: 197-203.
http://dx.doi.org/10.1002/art.1780390205
PMid:8849369
Ghosh S, May MJ and Kopp EB (1998). NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol. 16: 225-260.
http://dx.doi.org/10.1146/annurev.immunol.16.1.225
PMid:9597130
Longui CA and Faria CD (2009). Evaluation of glucocorticoid sensitivity and its potential clinical applicability. Horm. Res. 71: 305-309.
http://dx.doi.org/10.1159/000223413
PMid:19506386
Louzada-Junior P, Souza BDB, Toledo RA and Ciconelli RM (2007). Análise descritiva das características demográficas e clínicas de pacientes com artrite reumatóide no estado de São Paulo, Brasil. Rev. Bras. Reumatol. 47: 84-90.
http://dx.doi.org/10.1590/S0482-50042007000200002
McKay LI and Cidlowski JA (1999). Molecular control of immune/inflammatory responses: interactions between nuclear factor-kappa B and steroid receptor-signaling pathways. Endocr. Rev. 20: 435-459.
http://dx.doi.org/10.1210/er.20.4.435
PMid:10453354
, “Structural evaluation of type 3 dopaminergic receptor gene (DRD3) in chronic anovulatory women”, vol. 7, pp. 140-151, 2008.
, “A novel mutation in DAX1 gene causing different phenotypes in three siblings with adrenal hypoplasia congenita”, vol. 6, pp. 277-283, 2007.